Business Description
West Pharmaceutical Services Inc
NAICS : 339112
SIC : 3841
ISIN : US9553061055
Total Employee Number:
10,800Compare
Compare
Traded in other countries / regions
WST.USAWPS.GermanyW2ST34.Brazil1WST.ItalyWST.Mexico IPO Date
2021-02-26Description
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.65 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.37 | |||||
Interest Coverage | 344.8 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 16.47 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.5 | |||||
3-Year EBITDA Growth Rate | -0.1 | |||||
3-Year EPS without NRI Growth Rate | -5.3 | |||||
3-Year FCF Growth Rate | 3.6 | |||||
3-Year Book Growth Rate | 6.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.07 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 100 | |||||
14-Day RSI | 99.99 | |||||
12-1 Month Momentum % | 18.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.71 | |||||
Quick Ratio | 2.04 | |||||
Cash Ratio | 0.77 | |||||
Days Inventory | 76.26 | |||||
Days Sales Outstanding | 68.24 | |||||
Days Payable | 43.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Payout Ratio | 0.11 | |||||
3-Year Dividend Growth Rate | 5.2 | |||||
3-Year Average Share Buyback Ratio | 0.9 | |||||
Shareholder Yield % | 1.44 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 36.28 | |||||
Operating Margin % | 21.41 | |||||
Net Margin % | 16.85 | |||||
EBITDA Margin % | 26.36 | |||||
FCF Margin % | 14.26 | |||||
OCF Margin % | 22.28 | |||||
ROE % | 18.3 | |||||
ROA % | 13.53 | |||||
ROIC % | 17.92 | |||||
3-Year ROIIC % | -19.72 | |||||
ROC (Joel Greenblatt) % | 28.07 | |||||
ROCE % | 19.82 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 46.91 | |||||
Forward PE Ratio | 34.17 | |||||
PE Ratio without NRI | 44.02 | |||||
Shiller PE Ratio | 55.08 | |||||
Price-to-Owner-Earnings | 59.6 | |||||
PEG Ratio | 8.15 | |||||
PS Ratio | 7.9 | |||||
PB Ratio | 8.32 | |||||
Price-to-Tangible-Book | 8.65 | |||||
Price-to-Free-Cash-Flow | 55.61 | |||||
Price-to-Operating-Cash-Flow | 35.6 | |||||
EV-to-EBIT | 36.55 | |||||
EV-to-Forward-EBIT | 26.96 | |||||
EV-to-EBITDA | 28.95 | |||||
EV-to-Forward-EBITDA | 21.2 | |||||
EV-to-Revenue | 7.63 | |||||
EV-to-Forward-Revenue | 5.41 | |||||
EV-to-FCF | 53.67 | |||||
Price-to-GF-Value | 0.97 | |||||
Price-to-Projected-FCF | 3.94 | |||||
Price-to-DCF (Earnings Based) | 1.32 | |||||
Price-to-DCF (FCF Based) | 1.41 | |||||
Price-to-Median-PS-Value | 1.21 | |||||
Price-to-Graham-Number | 4.12 | |||||
| Price-to-Net-Current-Asset-Value | 35.15 | |||||
Earnings Yield (Greenblatt) % | 2.74 | |||||
FCF Yield % | 1.85 | |||||
Forward Rate of Return (Yacktman) % | 2.4 |
West Pharmaceutical Services Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
West Pharmaceutical Services Inc Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-23 08:00 | In 117 days | ||
| Third quarter earnings results for 2026 | 2026-10-23 | In 116 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 08:00 | In 26 days | ||
| Second quarter earnings results for 2026 | 2026-07-24 | In 25 days | ||
| William Blair Annual Growth Stock Conference | 2026-06-02 16:00 | 5,112.51 (+0.00%) | ||
| Bank of America Global Healthcare Conference | 2026-05-20 14:20 | 5,112.51 (+0.00%) | ||
| General meeting for 2026 | 2026-05-04 09:30 | 5,112.51 (+0.00%) | ||
| USD 0.220000 Cash Dividend | 2026-04-29 | 5,112.51 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 08:00 | 5,112.51 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 5,112.51 (+0.00%) |
Show
Entries
Press Release
Articles on West Pharmaceutical Services Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers